WATCH: Trump administration officials announce PTSD research funding for psychedelic drug ibogaine
Summary
The Department of Health and Human Services will award up to $4.9 million to prepare for U.S. studies of ibogaine as a potential treatment for post-traumatic stress disorder. The funding will support work on manufacturing, dosing and study design, not research involving patients.Key Facts
- Health Secretary Robert F. Kennedy Jr. announced the funding on Thursday alongside Veterans Affairs Secretary Doug Collins.
- Ibogaine is a psychedelic drug made from a shrub native to West Africa.
- Ibogaine can cause hallucinations, nausea, vomiting, tremors and potentially deadly irregular heart rhythms.
- Ibogaine is illegal in the United States and is classified with drugs such as LSD and ecstasy.
- The federal effort will focus first on safety and research design, Collins said.
- The government will receive data and treatment guidance from Beond Inc., a Texas-based company that has treated more than 3,000 patients with ibogaine in Mexico.
- President Donald Trump signed an order in April directing federal agencies to speed review and research of psychedelics that could help treat mental health conditions.
- Ibogaine clinics often charge $10,000 to $20,000 for a course of treatment and monitor patients' heart readings.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
